Tag: Scientific Informatics
D360 Overview
Certara Announces Appointment of President of its Software Division
PRINCETON, N.J.—September 17, 2020. Certara, the global leader in biosimulation, today announced the appointment of Leif E. Pedersen as president of its software division, reporting to Chief Executive Officer William F. Feehery, PhD. Mr. Pedersen is a seasoned software industry executive with more than 25 years of experience across a range of software categories. He … Continued
Large pharmaceutical company uses D360 data informatics technology to advance its neurological discovery program
Reduce IT Maintenance Overhead with D360
Arvinas Selects Certara to Advance Speed and Efficiency of its Targeted Protein Degradation Research
PRINCETON, NJ – Feb. 10, 2020 – Arvinas Selects Certara to Advance Speed and Efficiency of its Targeted Protein Degradation Research
Certara Introduces Version 19.6 of its D360 Scientific Informatics Platform
The ability to analyze and visualize sequence-activity relationships in proteins and peptides added to D360’s biologics toolkit for drug discovery research
Certara Launches Version 19.1 of its D360 Scientific Informatics Platform
PRINCETON, NJ – February 21, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced the launch of version 19.1 of its flagship scientific informatics platform D360.
Certara’s D360 Version 10.5 Extends Platform’s Ability to Optimize Discovery Research Across Therapeutic Modalities
August 16, 2018 – Certara today announced the launch of D360 v10.5, the first in a series of releases focused on delivering biologic-relevant tools together with D360’s data access capabilities.
Certara’s Best of the Blog 2017
A selection of short essays from our blog, written to empower our customers with modeling and simulation (M&S) and regulatory writing solutions in order to help them solve the toughest drug development problems. Certara staff contributions range in topic from pharmacometrics to systems biology to the growing importance of regulatory writing and sharing clinical trial results.